Table 2.
STAT5A/STAT5B relative contribution and STAT5 DNA binding characteristics on the known and novel STAT5 target genes evaluated in this study
| RT-qPCR | ChIP assay | |||||||
|---|---|---|---|---|---|---|---|---|
| Gene name | Accession no. | % inhibition in 5AB KD | STAT5 binding | % of input DNAb | STAT5 binding sitec (positions relative to tss) | References | IL-3 induction profile | |
| STAT5A or STAT5B | ||||||||
| 1 | Cytokine inducible SH2-containing protein (Cis)a | NM_009895 | 59 | + | 6 | 4 c. in tandem (−230/−103) | (10,48), this study | Early, sustained |
| 2 | Cytokine inducible SH2-containing protein 3 (Socs-3)a | NM_007707 | 54 | + | 3.5 | 2 c. + 1 n.c. in tandem (−345/−64) | (53), this study | Early, transient |
| 3 | Oncostatin M (Osm)a | D31942 | 59 | + | 4 | 2 c. in tandem (−190/−95) | (93), this study | Early, transient |
| 4 | MAP kinase phosphatase 1 (MKP-1) | X61940 | 52 | + | 0.4 | 2 c. in tandem (−3450/−3414) | This study | Early, transient |
| 5 | Stimulated by retinoic acid 13 (stra13/clast5) | NM_011498 | 67 | − | − | [2 c. −680/−410] | This study | Early/late, sustained |
| 6 | Serine/threonine kinase (Pim-2) | L41495 | 56 | − | − | [4 c. −1520/−270] | This study | Late, sustained |
| 7 | Interleukin 2 receptor, beta (IL-2Rβ) | M28052 | 59 | − | − | [1 c. −5840; 1 c. +2725] | This study | Late, sustained |
| 8 | Heparin binding epidermal growth factor-like growth factor | NM_010415 | 71 | ND | ND | ND | This study | Late, sustained |
| 9 | Serine/threonine kinase (Pim-1)a | NM_008842 | 35 | ND | ND | ND | (10), this study | Early, sustained |
| 10 | T-cell receptor gamma, variable 4 (TCRγ-V4)a | NM_011558 | 36 | ND | ND | ND | (10), this study | Late, sustained |
| STAT5A and STAT5B | ||||||||
| (i) Equal contribution | ||||||||
| 11 | Cytokine inducible SH2-containing protein 1 (Socs-1)a | NM_009896 | 52 | + | 0.6 | 2 c. + 1 n.c. in tandem (−2095/−2061) | This study | Early, transient |
| 12 | G-protein coupled receptor; anaphylatoxin C3a receptor 1 (C3ar1) | NM_009779 | 91 | + | 1.1 | 7 n.c. (−2085/−1520) | This study | Early, sustained |
| 13 | TNFRSF13b | NM_021349 | 86 | + | 3 | 2 c. (+1662/+1735, intron 2) | This study | Late, sustained |
| 14 | Receptor-like tyrosine kinase (Ryk) | L21707 | 79 | − | − | [1 c. −2190; 7 n.c. −4150/+1] | This study | Late, sustained |
| 15 | Schlafen 2 (Sfln2) | NM_011408 | 90 | − | − | [no c. in promoter; 4 c. +4130/+5040] | This study | Late, sustained |
| 16 | p21 (WAF1/CIP1)a | NM_007669 | 66 | ND | ND | ND | (10), this study | Early, transient |
| (ii) A > B | ||||||||
| 17 | Serine (or cysteine) proteinase inhibitor (Spi2.1)a | M64085 | 85 | + | 0.9 | 1 c. + 1 n.c. in tandem (−127/−92) | (50), this study | Late, sustained |
| (iii) B > A | ||||||||
| 18 | Interleukin 2 receptor, alpha (IL-2Rα)a | NM_008367 | 90 | + | 2.5 | 1 c. + 1 n.c. in tandem (−1268/−1240) | (35), this study | Late, sustained |
| 19 | Interleukin 4 receptor, alpha (IL-4Rα) | M29854 | 62 | ND | ND | ND | (10), this study | Early, sustained |
| STAT5B specific | ||||||||
| 20 | Enabled homolog (Drosophila) (enah); Mena; VASP; WASP | NM_010135 | 79 | ND | ND | ND | This study | Late, sustained |
| 21 | Laminin, alpha 5 (Lama5) | U37501 | 82 | ND | ND | ND | This study | Late, sustained |
| ? | ||||||||
| 22 | Helix-loop-helix DNA binding protein regulator (Id-1)a | M31885 | 0 | + | 1.6 | 1 c. + 2 n.c. in tandem (+5350/+5710) | (11), this study | Early/late, sustained |
| 23 | Myelocytomastosis oncogene (c-Myc)a | X01023 | 0 | ND | ND | ND | (10), this study | Early, sustained |
| 24 | Bcl-xa | L35049 | 0 | ND | ND | [2c. in tandem, +386/+475, intron 1] | (10,39,85), this study | Late, sustained |
aKnown STAT5 target genes from the literature.
bNo antibody control generated background values of 0.01–0.1% of input DNA (see also Figure 4).
cValues in square bracket indicates putative binding motifs found in the genomic sequence that showed no STAT5 binding by ChIP.
Abbreviations: c., consensus; n.c., non-consensus; ND, not determined; tss, transcription start site.